Oxytocin to Enhance Integrated Treatment for AUD and PTSD
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the proposed Stage II study is to examine the efficacy of oxytocin
(OT) as compared to placebo in reducing (1) alcohol use disorder (AUD) symptoms, and (2)
post-traumatic stress disorder (PTSD) symptoms among Veterans receiving COPE therapy
(Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure). To
evaluate purported neurobiological mechanisms of change, we will employ functional magnetic
resonance imaging (fMRI) at pre- and post-treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of South Carolina
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)